265 related articles for article (PubMed ID: 36648385)
1. Emerging care management strategies for severe asthma: integrating biologic therapy.
Spjut R
Am J Manag Care; 2022 Sep; 28(11 Suppl):S203-S209. PubMed ID: 36648385
[TBL] [Abstract][Full Text] [Related]
2. Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics.
Bourdin A; Brusselle G; Couillard S; Fajt ML; Heaney LG; Israel E; McDowell PJ; Menzies-Gow A; Martin N; Mitchell PD; Petousi N; Quirce S; Schleich F; Pavord ID
J Allergy Clin Immunol Pract; 2024 Apr; 12(4):809-823. PubMed ID: 38280454
[TBL] [Abstract][Full Text] [Related]
3. Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma.
Chan R; RuiWen Kuo C; Lipworth B
J Allergy Clin Immunol Pract; 2020; 8(10):3363-3370. PubMed ID: 32673880
[TBL] [Abstract][Full Text] [Related]
4. Biologics in severe asthma: the overlap endotype - opportunities and challenges.
Bakakos A; Loukides S; Usmani OS; Bakakos P
Expert Opin Biol Ther; 2020 Dec; 20(12):1427-1434. PubMed ID: 32779950
[TBL] [Abstract][Full Text] [Related]
5. Role of Biologics in Asthma.
McGregor MC; Krings JG; Nair P; Castro M
Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
[TBL] [Abstract][Full Text] [Related]
7. The management of severe asthma in 2020.
Côté A; Godbout K; Boulet LP
Biochem Pharmacol; 2020 Sep; 179():114112. PubMed ID: 32598948
[TBL] [Abstract][Full Text] [Related]
8. Current and future targeted therapies for severe asthma: Managing treatment with biologics based on phenotypes and biomarkers.
Santus P; Saad M; Damiani G; Patella V; Radovanovic D
Pharmacol Res; 2019 Aug; 146():104296. PubMed ID: 31173886
[TBL] [Abstract][Full Text] [Related]
9. Biologics for severe asthma-Which, when and why?
Shah PA; Brightling C
Respirology; 2023 Aug; 28(8):709-721. PubMed ID: 37222237
[TBL] [Abstract][Full Text] [Related]
10. Emerging Biologics in Severe Asthma.
Pavord ID; Hilvering B; Shrimanker R
Immunol Allergy Clin North Am; 2016 Aug; 36(3):609-23. PubMed ID: 27401629
[TBL] [Abstract][Full Text] [Related]
11. Treatment for Severe Asthma in Children: What About Biologics?
Pansare M; Seth D; Kamat D; Poowuttikul P
Pediatr Ann; 2021 May; 50(5):e206-e213. PubMed ID: 34044704
[TBL] [Abstract][Full Text] [Related]
12. Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma.
Pavord ID; Hanania NA; Corren J
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):410-419. PubMed ID: 34958982
[TBL] [Abstract][Full Text] [Related]
13. Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far?
Parulekar AD; Diamant Z; Hanania NA
Curr Opin Pulm Med; 2017 Jan; 23(1):3-11. PubMed ID: 27820746
[TBL] [Abstract][Full Text] [Related]
14. Biological treatments for severe asthma.
Assaf SM; Hanania NA
Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):379-386. PubMed ID: 31169594
[TBL] [Abstract][Full Text] [Related]
15. Factors to Consider in Prescribing Asthma Biologic Therapies to Children.
Anderson WC; Banzon TM; Chawes B; Papadopoulos NG; Phipatanakul W; Szefler SJ
J Allergy Clin Immunol Pract; 2023 Mar; 11(3):693-701. PubMed ID: 36646381
[TBL] [Abstract][Full Text] [Related]
16. Prospects for new and emerging therapeutics in severe asthma: the role of biologics.
Kepil Özdemir S; Bavbek S
Expert Rev Respir Med; 2017 Jun; 11(6):505-512. PubMed ID: 28464704
[TBL] [Abstract][Full Text] [Related]
17. Biologics in pediatric lung disease.
McGhee SA
Curr Opin Pediatr; 2018 Jun; 30(3):366-371. PubMed ID: 29538045
[TBL] [Abstract][Full Text] [Related]
18. Promises and challenges of biologics for severe asthma.
Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
20. Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent.
Krings JG; McGregor MC; Bacharier LB; Castro M
J Allergy Clin Immunol Pract; 2019; 7(5):1379-1392. PubMed ID: 31076056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
